Effects of administration of fostamatinib on blood concentrations of warfarin in healthy subjects

Study identifier:D4300C00013

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin when Co-Administered with Fostamatinib in Healthy Subjects

Medical condition

Rheumatoid Arthritis, Healthy subjects

Phase

Phase 1

Healthy volunteers

Yes

Study drug

warfarin, fostamatinib

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Mar 2011

Primary Completion Date: 01 May 2011

Study Completion Date: 01 May 2011

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Apr 2014 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions
Experimental: warfarin	Drug: warfarin 2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart Other Name: Marevan
Experimental: warfarin and fostamatinib	Drug: warfarin 2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart Other Name: Marevan Drug: fostamatinib 2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days

"There is no result for the study"

Documents available

D4300C00013 Clinical Report Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

Saadia Ahmad

+44 (0) 20 7910 7762

Saadia.Ahmad@quintiles.com

Investigators

Principal Investigator

James Ritter

Quintiles, Phase 1 Unit, London